Skinvisible, Inc. (SKVI)

OTCMKTS: SKVI · Delayed Price · USD
0.00 (0.00%)
Mar 15, 2023, 12:00 AM EDT - Market closed
Market Cap 458.98K
Revenue (ttm) 527,151
Net Income (ttm) -989,692
Shares Out 4.54M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 160
Open 0.101
Previous Close 0.101
Day's Range 0.101 - 0.101
52-Week Range 0.101 - 0.250
Beta -0.30
Analysts n/a
Price Target n/a
Earnings Date n/a

About SKVI

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over the counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company offers sunless tanning and sunscreen products under the Skinbrella name. It also licenses to pharmaceutical and consumer goods companies; assists p... [Read more]

IPO Date Jan 7, 1999
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol SKVI
Full Company Profile

Financial Performance

In 2021, Skinvisible's revenue was $663,426, an increase of 140.76% compared to the previous year's $275,556. Losses were -$1.07 million, -25.89% less than in 2020.

Financial Statements


Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug

LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received U...

10 months ago - Accesswire